The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call
Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to "tangible signs of a more constructive spending environmen
Yahoo22 gün önceRVTY
Revvity (RVTY) Q2 2026 Earnings Call Transcript
Diagnostics surged 11% organically as AI-driven demand accelerated.
Yahoo23 gün önceRVTY
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass., August 11, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:
Yahoo24 gün önceRVTY
Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing
WALTHAM, Mass., August 10, 2026--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows.
Yahoo25 gün önceRVTY
1 Profitable Stock on Our Buy List and 2 We Find Risky
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
Yahoo25 gün önceRVTY
Revvity Q2 Earnings Call Highlights
Revvity (NYSE:RVTY) reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows
Yahoo26 gün önceRVTY
Does Revvity’s Q2 Beat, Higher Guidance and China Exit Alter the Bull Case for RVTY?
Revvity, Inc. reported past second-quarter 2026 results with sales of US$729.69 million, net income of US$51.82 million and diluted EPS from continuing operations of US$0.48, while also reaffirming a regular US$0.07 per-share quarterly dividend and issuing full-year 2026 revenue guidance of US$2.83 billion to US$2.86 billion. Management attributed the earnings beat and raised outlook to improving pharma and biotech spending, strong Diagnostics growth, especially in reproductive health and...
Yahoo29 gün önceRVTY